Member Info for Happyish

Great post.

Typo, testing

So, like all of us, I haven’t a clue what will happen to the price in the morning, nor the day after, the week after, or the month after.

However, even without the direct DHSC test approval, this Investment is worthwhile far more than the current SP suggests, from overseas sales potential alone (NB I know the de-rampers’s stance already).
For me, this has been a huge political play. The UK Gov knew Cummings was going to deliver a tirade of accusations (probably, in the main, with some kind of base), so have held back good news ref UK Vaccine.
May sound blindingly hopeful, but that’s how I see the current state of affairs.

You're very welcome.
From listening into the last few of these presentations, it's clear that he's trying to focus minds on the future of Tiziana. Up until Sunday, that was incredibly frustrating as there was a distinct amount of radio silence ref Accustem. The Sunday Roast interview (https://t.co/IaFvsJU5Dq?amp=1) with the main man has at least given some dialogue for investors to follow (however late and confused it has been).
My big takeaway is the $125 billion market that Foralumab is trying to break into - wow !!!
Best of luck to the trial patient.

https://t.co/IaFvsJU5Dq?amp=1 - hopefully will give answers to Accustem questions.

https://zoom.us/j/96136565588?pwd=aXl3eTNhUCtBQm9sSU9nMU1aSnlDQT09
Passcode: 109499

* continuing
http://www.stockchallenge.co.uk/ftse.php

Good evening all

Contiuing on from my previous posts, TILS will join the FTSE All-Share Index when changes take effect this coming Monday (http://www.stockchallenge.co.uk/ftse.php)

This is likely to be a very busy 'buying' day as Trackers take positions in TILS.

GLA

My takeaways from the call:
It was good to hear Kunwar run though the top line data results for the Brazil Phase 1 trial. These show that there is merit in moving to a further trial with a greater number of patients, including those with severe disease. This could lead to Government / Pharma interest. News on when this can be started will to be announced shortly.
Whilst these trials are important, it seems the real drivers (‘Key Milestones’, as Kunwar referred to them) are Crohns and MS. They are much further along with these and there appears to be real interest from Pharma’s. End 2021 should be very interesting.
They didn’t want the call to be side-tracked by Accustem questions. They’ll update us when they can (or want to).

Hi Shakin
As others have highlighted, TILS has already left AIM for the Main Market.
3rd March relates to the date that the revised FTSE All-Share Index constituents get rebased. AIM Companies cannot be part of this, only main listed Companies.
The actual changes occur on 22 March so, up to this date, TILS will be on the main market, but not attached to any recognised index.
From 22 March, TILS could benefit from being part of the FTSE All-Share Index tracker funds.
Hope that helps.

On top of the Company announcements we may expect, the FTSE All-Share Index entry is in our sights.

As at 10 February, TILS were ranked 503 in the FTSE All-Share Index Ranking, when the share price was 138.50 and the Market Cap was £269.50 million.

At that date, the FTSE Small Cap entry / exit level was for Companies with a Market Cap of £166.80 million.

So, even with the recent falls, TILS is in an extremely healthy position to replace one of the existing FTSE All-Share constituents, when this is reviewed on 3 March 2021 (approx two and a half trading weeks away). This should be an extremely busy trading day as FTSE-All Share Trackers will need to react.

A benefit, to remember, of leaving AIM and joining the main market !!!

As always GLA

Source - www.stockchallenge.co.uk/ftse.php

Less than 5 mins and all (hopefully) will be revealed.

GLA

Thanks for the description Axe-Capital.
But why drop this filing at the end of a trading day when investors have been reassured that funding is in place for the next 2 years?
Why not wait until the market reacts to any Brazil news, then think about and communicate the concept of further fund raising?

Wow, feels like Groundhog day again - back to ATMs and a significant 'out of the blue' placing. How many more times?
The Brazil data must be some kind of spectacular, with significant interest either shown, or expected, from real serious investors against the backdrop of a tiny free float (the recent Conference must have gone well or Pharma's are lining up for entry).
A real head scratcher though.
Wonder if the results will be first thing or held for US open. Gonna be interesting.
As always GLA

KV3MC Well done for banking at that price.

Only time will tell (by 3/3/2021) whether you're other fish will reap greater rewards.

GLA

Less than an hour left of AIM 'casino' for the proper market, with proper participants and I'm now back in the blue.

Wouldn't be surprised to see a flyer from 8 AM tomorrow.

GLA

Thanks Oldapache and Rokerpark

GLA

Thanks 0752neil and Oldapache.

Bombaysapphire, “We're in the money, we're in the money. Peeps saying getting into the FTSE might even lower the price but thats got to be cobblers if the trackers have to buy in isn't it ?”

If the Main Market finds TILS to be a similar value to the Aim close, then I would expect this to be the case. Rises into entry into FTSE All-Share Index on 3 March 2021.
Also, ‘active’ Fund Managers that benchmark against the performance of the FTSE All-Share Index are likely to take a keen interest if TILS price is projected to rise (they are unlikely to want to lag any shortfall in performance by sitting on the side-lines).

What I’m unsure of, so has anyone any experience of this, is for UK Fund Managers who’s mandate is to benchmark against the FTSE All-Share Index, can they invest in the US ADRs (taking advantage of the current arbitrage opportunity), or are they limited to investing purely via the UK Main Market? And does this differ for Global Fund Managers?
This might start to explain part of the price differential?

Also, there was a small typo in my message of 15:20 yesterday, it should have read:
“So, TILS are (comfortably) in a position where they should expect to automatically enter the FTSE All-Share Index on 3 March 2021, as their share price / market cap has moved sharply upwards since this was produced to approx. £293 million, I believe (which would take them into the top 500).”, not ‘400’ as stated. Although, the movements today are helping get to 400 quicker.

As always, no advice intended and my thoughts alone, so please DYOR.

GLA

Whilst having a spot of lunch, I’ve been doing some research on the constituents of the FTSE All-Share Index.

I thought I’d share what I found, but wish to apologise in advance if it appears to be seeking to teach others (more knowledgeable than me) how to suck eggs, if I've misread anything, or if this has been covered off previously by another poster(s).

The FTSE All-Share Index is a capitalisation-weighted index (i.e. league table based on biggest to smallest companies) comprising around 600 of more than 2,000 companies traded on the London Stock Exchange (LSE). Since 29 December 2017, the constituents of this index totalled 641 companies.

The FTSE All-Share is the aggregation of the FTSE 100 Index and the FTSE 250 Index and the FTSE SmallCap Index. Importantly, with regard to TILS, this Index does not include Companies listed on the FTSE AIM Index, as they have to be registered on the Main Market.

The FTSE constituents are reviewed every quarter (March, June. September and December). At each review some companies will exit and others will enter. This is a busy trading day. The next quarterly review is 3 March 2021.

The following link shows the most up-to-date market-weighted league table I could find - http://www.stockchallenge.co.uk/ftse.php

This shows TILS’s position was 531, with a market cap of 208.20 (as at 23 December 2020). It also shows the FTSE All-Share entry point was 159.4.
So, TILS are (comfortably) in a position where they should expect to automatically enter the FTSE All-Share Index on 3 March 2021, as their share price / market cap has moved sharply upwards since this was produced to approx. £293 million, I believe (which would take them into the top 400).

Any thoughts anyone? Unless the share price slumps significantly, I can only see strong Institutional investing at initial launch / in to the beginning of March. That's before any other news.

No advice intended and my thoughts alone, so please DYOR.

As always GLA

Good morning all
Is it safe to come out from hiding?
Looks like (if you include potential Accustem price) I could be back in the money. Absolutely glorius (shame pubs are closed as more difficult to celebrate). Well done LTH's and those able to pick up on the cheap.
And what a pipeline of news that could flow this month and quarter.
As always, GLA